Dr. Lee Chee Wee, Chairman

Dr. Lee Chee Wee was appointed as the Chairman of DynaLynk Pharma in 2007. He is also the Founder and Chief Executive Officer of Lynk Biotechnologies and has over twenty years of experience in drug discovery and development processes. Dr. Lee received his B.Sc. and M.Sc. from McGill University, Canada, and his Ph.D. from the University of Alberta, Canada. He is also a recipient of the Alberta Heritage Foundation Scholarship for Medical Research (AHFMR). He had carried out his Post-doctoral Fellowship at Yale Comprehensive Cancer Centre and Department of Pharmacology at Yale University School of Medicine, USA, before coming to Singapore to pursue his academic career at the Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, where he is currently an Associate Professor.

Dr. Tan Boon Tiong, Director

Dr. Tan Boon Tiong was appointed a director of DynaLynk Pharma in 2007.  He is also an independent director of Lynk Biotechnologies. Dr. Tan has wide-ranging experience in the telecommunications and information technology industries.  While at SingTel from 1996 to 2000, he headed the technology development department.  He later joined Mediacorp Singapore in 2000 where he managed a S$100 million technology fund and led in Mediacorp's efforts in developing its New Media business.  Dr. Tan was also Director of the National University of Singapore Venture Support Division where he spearheaded the funding and incubation of technology start-ups from NUS.  Dr. Tan holds a Ph.D. from Cambridge University.

Mr. Lawrence Yu, Director

Mr. Lawrence Yu is the founder and President of Dynavest Pte Ltd where he leads in the strategic management of the organisation’s global operations.  Before founding Dynavest, he was the Vice President (Far East Operations) of a US corporation, which was a Fortune 500 company in Hong Kong, from 1966 to 1978.